



European College of Neuropsychopharmacology
ECNP Research & Scholarship Foundation

Annual report 2018



Contents

About ECNP	4
President's Introduction	6
Overview of Activities	8
- Education	9
- Science	12
- Outreach	14
Treasurer's Report	16
- Financial Statements	18
Executive Director's Report	23
Report of the External Review Board	24
Governance	26

This report covers two legally autonomous entities: the European College of Neuropsychopharmacology, a Swiss-constituted member society (hereafter ECNP Association); and the Netherlands-based ECNP Research and Scholarship Foundation (hereafter ECNP R&S).

For the purposes of simplicity they are here collectively referred to as "ECNP" or "the College."



Both ECNP Association and ECNP R&S are public-interest-serving entities (algemeen nut beogende instellingen – ANBI) under Dutch tax law.

About ECNP



ECNP is an independent European scientific association that exists to promote high-quality experimental and clinical research in applied and translational neuroscience with a view to stimulating the development of better treatments for those suffering disorders of the brain.

Our mission: to advance the science of the brain, promote better treatment and enhance brain health.

- More than 20 scientific meetings held every year
 - Spanning all aspects of scientific, educational, and regulatory dialogue
 - Bringing together researchers and clinicians from over 100 countries for fruitful scientific exchange
- 300 young scientists trained every year
 - Paid for by ECNP
- A major international journal *European Neuropsychopharmacology*

Why we are here

By promoting new and better treatments for disorders of the brain ECNP aims to reduce the prevalence of these diseases and to alleviate the enormous suffering they cause.



Proportion of Europeans who suffer from a mental disorder annually

38%

(*Eur Neuropsychopharmacol* 2011) ¹

Number of premature deaths among people aged 25-64 due to mental health problems and suicide across Europe

50,000

(*OECD/EU* 2018) ²



Number of deaths caused every year in Europe by brain disorders

1.2 million

(*OECD/EU* 2018) ²



Total cost per annum of disorders of the brain to Europe

4% of GDP

(*OECD/EU* 2018) ²



Reduction of life expectancy due to severe mental disorders

10 to 25 years

(*WHO* 2014) ⁴

Proportion of mental disorders that start before the age of 24

70%

(*Nat Rev Neurosci* 2008) ³



1) H.-U. Wittchen, et al. *The size and burden of mental disorders and other disorders of the brain in Europe 2010*. *Eur Neuropsychopharmacol*. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018.

2) *Health at a Glance: Europe 2018. State of Health in the EU Cycle*. <http://www.oecd.org/health/health-at-a-glance-europe-23056088.htm>

3) T. Paus, M. Keshavan, J. N. Giedd. *Why do many psychiatric disorders emerge during adolescence?* *Nat. Rev. Neurosci*. 2008; 9.12: 947-578

4) *Premature death among people with severe mental disorders*. https://www.who.int/mental_health/management/info_sheet.pdf

President's introduction

2018 was another year of remarkable activity and achievement for ECNP. In terms of its contribution to building the field and supporting the cause of applied and translational neuroscience in Europe, ECNP continues to lead the way.

No other independent, non-governmental organisation in Europe connects more neuroscientists, psychiatrists, psychologists and neurologists, trains more early career scientists, supports more research networks, or confers more awards. It is a record of which we are extremely proud.

ECNP has been able to do this, in the first instance, because of the extraordinary level of commitment and engagement from hundreds of volunteers dedicating collectively thousands of hours of their time, as well as their ideas, energy, enthusiasm and verve. ECNP would not exist without them.

ECNP is also fortunate in having a strong capital position, and these reserves have been critical in allowing the College to maintain the breadth and momentum of its activities. We owe these reserves to the foresight, acumen and restraint of previous executive committees, and we are acutely aware of the responsibilities that come with them. The following report aims to demonstrate the care and seriousness with which the College is discharging those responsibilities – both to maximise the use of ECNP's resources and to ensure their long-term sustainability.

For all its dynamism, however, ECNP remains a small organisation – small in absolute terms, and small relative to the problems ECNP exists to address. Success is measured by impact. And having an impact requires rigorous focus. The last three years have been marked by an ongoing programme of assessment and realignment to ensure the College's resources are concentrated as efficiently as possible on the areas of greatest urgency and need. The priority has been to target issues that are of high relevance to our user group, region-wide in their scope and implications, and on which ECNP can make a meaningful impact.

Education. Translational neuroscience mediates between better defined disciplines in basic neuroscience on the one side and clinical psychiatry and neurology on the other. The field's educational infrastructure has, as a consequence, always been less well developed. Addressing this gap, with translational education for researchers and neuroscience-informed training for clinicians, especially as it applies to the use of medicines, remains a critical priority.

Science. Propagating excellent science remains fundamental to the ECNP mission, not just amongst scientists to stimulate new and better research, but to clinicians, to encourage more scientifically informed treatment and, ultimately, better patient outcomes. Closely allied is the College's role as a facilitator of networks to connect researchers across the region and leverage Europe's scientific scale and depth to help address the biggest research questions.

Outreach. ECNP's independent and non-aligned status allows it to function as a connector between the field's various stakeholders in the academy, industry, regulatory bodies and the patient community. This platform function is vital to ECNP's role as facilitator of cross-talk and awareness-raising, part of its larger mission to support neuroscience across the treatment lifecycle.


The recent re-emergence of early phase clinical trials of drugs with different mechanisms of action, as well as the entry of new drugs on to the market, allows some cautious optimism that the problems that have beset the field in the last ten years, significantly impeding the development of new treatments, are beginning to be overcome. ECNP will continue to support these developments. Our mission is also taking us into new areas of science in the search for new treatment horizons, including genomics, proteomics and the digital revolution in diagnostics and therapeutics. These are exciting times in the field. ECNP has never been more needed.



Celso Arango
President



Overview of activities



ECNP Association Projects and Initiatives


- European Neuropsychopharmacology
- ECNP Neuropsychopharmacology Award
- European Affairs
- ECNP Brain Day
- European Brain Council, BioMed Alliance
- ECNP Co-morbidity Study

ECNP R&S Projects and Initiatives

- ECNP Workshop Neuropsychopharmacology
- ECNP Workshop on Clinical Research Methods
- ECNP School of Neuropsychopharmacology
- ECNP School on Child and Adolescent Neuropsychopharmacology
- ECNP Research Internship Programme
- ECNP Seminars
- ECNP Networks
- ECNP New Frontiers Meeting
- Neuroscience-based Nomenclature (Nbn)
- 'Introduction to Neuropsychopharmacology' SPOC

Education

Developing the next generation of European research and clinical leaders is a longstanding ECNP priority, and a major focus of the College's resources. Stimulating translational research, promoting the best-practice use of treatments, providing methods training, assisting with career development, and encouraging early career scientists from European developing-economy countries are critical goals.



Translational education
Filling the gap between fundamental research and the clinic

ECNP Internship Programme
 Short-term research internship opportunities for early career scientists, across the spectrum of applied and translational neuroscience.
 • 15 interns per annum in institutes across Europe
ECNP R&S provides organisational support and a € 1,000 grant to cover travel and accommodation expenses.

ECNP Workshop **ECNP Workshop for Junior Scientists in Europe**
 15-18 March 2018, Nice, France
 Three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience.
 • 95 participants from 23 countries
 • 11 speakers from 5 countries, including the United States
 • Keynote lecture by Sarah-Jayne Blakemore, United Kingdom
 • 8 junior scientists funded to speak at the 31st ECNP Congress, with 12 poster presenters receiving a € 500 Travel Award to attend the ECNP Congress
Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.

"Besides discussing my results it was a great opportunity to meet and connect to lots of different researchers from various subfields of neurosciences coming from countries all over Europe."



"Thank you very much for the opportunity to participate in ECNP School. It was a great experience. A great place, an excellent training program, wonderful food. A rare opportunity to get so many impressions and knowledge at the same time!"


ECNP School of Neuropsychopharmacology
 24-29 June 2018, Oxford, United Kingdom

A week-long course covering the fundamentals of neuropsychopharmacology through to the use of medications in individual indications, good clinical practice and optimal treatment and algorithms.

- 153 applications, 49 participants from 24 countries
- 17 participants from 9 different developing-economy countries
- 14 faculty from 7 countries

Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.


ECNP School of Child and Adolescent Neuropsychopharmacology
 8-13 April 2018, Venice, Italy

A week-long residential programme of intensive training in clinical neuropsychopharmacology for child and adolescent psychiatrists.

- 122 applications, 47 participants from 26 countries
- 16 participants from 10 developing/economy countries
- 16 faculty from 6 countries

Registration, tuition, accommodation and food provided by ECNP R&S.

"One of the most valuable and beautiful experiences of my life."

"This is a fundamental course for junior scientists... Professor Vieta and all the speakers had an incredibly effective way to both capture our attention and to teach us something that is not learnable in books."


ECNP Workshop on Clinical Research Methods
 7-9 November 2018, Barcelona, Spain

Three days of training on research methodology and critical approaches to the scientific literature for early career scientists.

- 147 applications, 38 participants from 28 countries
- 12 participants from 10 developing-economy countries
- 10 faculty

Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.

Methods training
Specialist training in the theory and practice of pharmacological research

Clinical training I
Focused training for developing European countries

Clinical training II
Propagating best practices, training future clinical leaders

ECNP Small Private Online Course (SPOC): 'Introduction to Neuropsychopharmacology'

Online training course to prepare clinicians in ECNP educational activities, seminars, schools and internships.

- Modules covering neuroanatomy, neurophysiology, neurogenetics, psychopharmacology, immunology and statistics
- Due for release 2019

Funded by ECNP R&S.

BBSRC-ECNP Advanced Methods for Reproducible Science Workshop
 3-8 April 2018, Windsor, United Kingdom

Five-day residential course on advanced methods for reproducible science to raise the awareness of methods and to improve reproducibility across scientific disciplines.

- 30 participants

10 European participants funded by ECNP R&S.

ECNP Seminars in Neuropsychopharmacology
 23-25 March 2018, Volgograd, Russia
 20-22 April 2018, Odessa, Ukraine
 16-18 November 2018, St Petersburg, Russia

High-impact training courses for developing-economy countries, to enhance knowledge and skills in a concentrated learning environment with local and international experts.

- Volgograd 67 participants
- Odessa: 56 participants
- St Petersburg: 48 participants

Funded by ECNP R&S.

Nearly 1,000 junior scientists pass through ECNP events every year"



Science

The ability to connect Europe's applied and translational neuroscience community – from basic research all the way to clinical practice – and help to make it greater than the sum of its parts is central to ECNP's reason for existence.



31st ECNP Congress

6-9 October 2018, Barcelona, Spain

Europe's premier showcase for new research, treatments and technologies in applied brain science. Spanning human mood, behaviour, cognition and emotion, the congress covers the spectrum of CNS treatment research from basic science to clinical care.

- 5,056 participants from 100 countries
- 187 invited speakers and 86 chairs from 22 countries
- 1,195 abstracts submitted
- 745 posters and 180 e-posters
- 543 free registrations for junior scientist and CDE poster presenters
- 8 Seminar Awards of € 1,000 each to selected ECNP Seminar participants
- 52 Travel Awards of € 500 each for outstanding junior scientist poster abstracts
- 8 Poster Awards of € 500 each to presenters of outstanding posters
- 40 CDE Grants of € 500 each for submitters of exceptional abstracts from developing-economy countries

Presenting the best science

Disseminating the latest in CNS treatment research, building the ECNP community

World-class tools

Providing clinicians with the benefits of the latest neuroscience insights

Rewarding excellence

Recognising outstanding achievement



ECNP Neuropharmacology Award

Recognises exceptional research achievements in applied and translational neuroscience, alternating between basic and clinical science.



Winner 2018:
Marion Leboyer
France (clinical)

ECNP Association provides an unrestricted prize of € 10,000 – € 7,500 for the winner personally, and € 2,500 for a collaborator (or collaborators) of the winner's choice.

ECNP Preclinical Network Data Prize

The world's first prize for published 'negative' scientific results, aimed at encouraging the publication of data where the results do not confirm the expected outcome or original hypothesis.

Winner 2018: Laura Luyten and Tom Beckers, Belgium

Infrastructure provided by ECNP R&S. € 10,000 prize money awarded by Cohen Veterans Bioscience of Cambridge, MA.



European Neuropsychopharmacology

International journal in applied brain science, encompassing basic and clinical and research on the effects of centrally acting agents in the broadest sense.

- 12 issues per year
- Impact factor 2018: 4,468
- Total number of downloads 2018: 551,465
- Total number of citations in 2018: 1,336
- Ranked 27 out of 146 in psychiatry, 33 out of 199 in clinical neurology, and 63 out of 267 the neurosciences

Platforms for collaboration

Stimulating collaboration across Europe



Neuroscience-based Nomenclature

International collaborative venture, led by ECNP, to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science.

- Second revised edition released – also in book form – covering 133 medications
- New Child & Adolescent version released – also in book form
- 38,000 downloads of the app worldwide

Funded entirely by ECNP R&S.



ECNP Networks

Virtual, multi-centre European research clusters for the collection and aggregation of continent-wide clinical data, and for fostering research collaboration and ideas-sharing across the translational neurosciences.

- 13 Networks, covering a range of disorders and methods
- First Thematic Working Group (TWG) launched, on 'Prevention of mental disorders and mental health promotion'
- Grants obtained by the Bipolar Disorders Network, the Child and Adolescent Neuropsychopharmacology Network, the Down Syndrome and Other Genetic Developmental Disorders (DSG2D) Network, and the Experimental Medicine Network, with several more major proposals in the pipeline
- GRIDSAM multi-grid database system providing integrating data sets and facilitating more efficient data management and exploitation

ECNP R&S funds the Networks' and TWGs expenses, including meetings and data entry, and provides grants for proposal preparation.

Targeted Network Meetings

10 October 2018, Barcelona, Spain

Focused meetings to allow the ECNP Networks to address critical problems and themes with invited experts.

In 2018, there were three:

- Anxiety Disorders Network – Anxiety disorders across the lifespan
- Nutrition Network – Nutrition for mental health across the lifespan
- Suicide Network – Biomarkers for the prediction of suicidal behaviour

Meeting facilities and funds for nine speakers per TNM provided the 31st ECNP Congress Foundation.



Outreach

ECNP connects all of the key stakeholders in the CNS treatment arena, from researchers, to industry, regulators, policy-makers and patients – across the whole treatment cycle. Leveraging this position for the benefit of the field is a vital part of ECNP’s advocacy and awareness-raising role.

European Affairs

ECNP collaborates with a number of European societies to build European capacity and advance the interests of the field.

- Biomedical Alliance in Europe – member
- European Brain Council (EBC) – founding members
- European Federation of Psychiatric Trainees (EFPT) – supporter
- Federation of European Neuroscience Societies (FENS) – founding member
- Expert Platform on Mental Health – Depression (EPD) – supporter
- Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) – member

Funded by ECNP Association and ECNP R&S.

ECNP Co-morbidity Study

Major, three-year study with the London School of Economics (LSE) and Medical University of Vienna to provide a large-scale quantitative analysis of the frequency with which disorders of the brain coincide with somatic illnesses, and how this challenge is to be managed from a public health perspective.

- First study of this scale and complexity ever attempted
- Due to be published in 2019

Funded by ECNP R&S.

Moving the field forward

Bringing together key stakeholders

Joining forces

Working together to make the case for research and treatment

Informing the public

Communicating the latest in treatment science



ECNP New Frontiers meeting on Neurodevelopmental disorders

18-19 March 2018, Nice, France

A unique platform for scientists, industry leaders and regulators to address the pressing challenge of finding therapies for neurodevelopmental disorders – diseases which come with some of the highest unmet needs in the current medical landscape.

- 152 applicants from 38 countries
- 73 participants from 21 countries
- 12 speakers representing from 7 countries in Europe and North America
- Follow-up session at the 31st ECNP Congress in Barcelona

Organisation, facilities, registration, food and speaker expenses covered by ECNP



Regulatory Spotlight Session

9 October 2018, Barcelona, Spain

A special regulatory dialogue session with the European Medicines Agency (EMA), designed for open and active engagement amongst EMA stakeholders.

- Development of medicines in child and adolescent psychiatry
- Covering regulatory, academic, and industry perspective

Speakers and eight regulator subsidies provided by 31st ECNP Congress Foundation



ECNP Brain Day

5 October 2018, Barcelona, Spain

Public information day designed to bring the discoveries and excitement of frontier neuroscience to a general audience. Held annually in conjunction with the ECNP Congress.

- Organised in collaboration with the Spanish Biomedical Research Network in Mental Health (CIBERSAM) and the Facultad de Medicina, Universidad de Barcelona
- 7 speakers covering a variety of mental health topics
- 200 participants

Organisation, facilities, food and speaker expenses funded by ECNP Association.



Treasurer's report

The fundamentals of ECNP's financial position remain strong, with the College enjoying a sound capital base, strong market presence, and a beneficial tax environment.

As forecast, however, ECNP and R&S both reported significant deficits this year. These were due in part to lower proceeds from the 30th ECNP Congress¹ (Paris being an especially expensive city), which were expected; and a significant end-of-year dip in the equities markets (and hence in investment income), which was not. The deficits are consistent with the College's policy of limiting capital accumulation, in keeping with the agreement with the Dutch tax authorities that underpins our tax-exempt status. We anticipate future deficits as we continue to bring our capital position into alignment with the agreed cap.

The key priorities going forward:

- Proactive tax and regulatory compliance
- Capital preservation – at agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

Risks

ECNP is sustained by income from essentially two sources: fundraising at the ECNP Congress, and the proceeds of our investment portfolio; with additional revenue from membership subscriptions and the ECNP journal.

The investments

While the capital markets have been extremely effective generators of return over the long term, short-term results – especially since 2008 – have been highly unpredictable. Market volatility is hard enough to manage at the best of times, but because much of the instability since 2008 has been driven by geopolitical events rather than economic fundamentals, it has been especially difficult. ECNP is adjusting to this environment by continuously monitoring our investment strategy and recalibrating risk and return expectations on an ongoing basis.

The ECNP Congress

The congress is ECNP's largest and most complex activity, its most important in terms of projecting the ECNP mission, and its primary fundraising vehicle. Its ongoing health and vitality is therefore of vital interest to the College and risks surrounding it are carefully watched. These include:

- **Political disturbance.** ECNP has already experienced some of this, with the 2015 Paris terrorist attacks still to some extent reverberating during the 30th ECNP Congress in Paris in 2017, and, in a very different form, the effects of the 2017-18 Catalan separatist crisis on the 31st ECNP Congress in Barcelona. In both cases the impact, in terms of depressed registrations, was slight, but nevertheless provided examples of the congress's exposure to a generally less stable world.

¹) Congress proceeds are booked in the year after the congress occurs.

- **Climate reform.** International congresses are heavily dependent on low-cost air travel. Swedish already has a word – *flygskam* – for “flight shame,” reflecting a wider trend of changing attitudes to the sustainability of short-haul flights. If this feeling intensifies, it is reasonable to assume that at some point legislation will follow.

- **Technological disruption.** Congresses are a form of information technology, and informational technology is notoriously susceptible to seismic and often sudden disruption. While we believe there will always be a demand for face-to-face meetings, whether this demand will continue to be able to answer ECNP's fund-raising goals remains to be seen.

- **Market shifts.** International congresses have long served as important outreach vehicles for industry, and the revenue derived from these activities has helped to support the ECNP Congress's financial viability. It is the expectation that this support will decrease over time, as the economics of the industry change and the regulations governing continuing medical education (CME) become more restrictive. The continuing proliferation of meetings is also putting increased pressure on attendance and fragmenting audiences.

The journal

ECNP has enjoyed a 30-year relationship with Elsevier. The future of subscriptions journals, however – with the rise of open-access publishing, and especially Science Europe's proposed ‘Plan S’ – remains very unclear. However, although the renegotiation of the agreement in 2017 resulted in a considerably more favourable royalty arrangement for ECNP, the journal generates only a relatively small part of the College's overall income.

Membership

While membership numbers have remained broadly stable, changing demographics and consumer priorities have in general worked against the value traditionally accorded to membership of societies and associations. The College continues to work on this challenge. We see membership however as a good in itself, not as a source of income.

Future strategy

The College anticipates continuing deficits as it seeks to comply with the capital cap agreed with the Dutch tax authorities (a condition of ECNP Association's tax-exempt status) in 2012. The focus of this strategy will be on (a) time-bound expenditures, to avoid permanent, structural costs, and (b) investments in new areas of activity that will diversify the College's income base as a hedge against the risks outlined above. Time-bound expenditures include the co-morbidity study being conducted with the London School of Economics and Vienna Medical School, as well as the planned ‘small private online course’ (SPOC), an important new foray for ECNP into online education. Longer-term investments include the development of new delivery channels and the cultivation of a new audiences.

It is hoped that through these measures ECNP's long-term financial sustainability can be secured, and the College can continue to deliver its exceptional array of programmes without eroding its underlying capital reserves. Given the economic and political uncertainties ahead, this remains challenging. However, the College is confident that, to the extent it can be, it is prepared.

Eduard Vieta
Treasurer

Financial statements

ECNP Association

Balance sheet as at 31 December 2018 (in €)

(after appropriation of profit/losses)

	31-12-2018	31-12-2017
ASSETS		
CURRENT ASSETS		
Accounts receivable		
Debtors	4,740	398
Amounts owed by other foundations	197,522	213,272
Taxes	9,922	393
Other accounts receivable	182,557	248,721
	<u>394,741</u>	<u>462,784</u>
Securities	13,004,009	12,409,727
Bank Deposits	1,656,347	2,359,131
	<u>15,055,097</u>	<u>15,231,642</u>
EQUITY		
Other reserves	14,763,857	15,032,103
CURRENT LIABILITIES		
Trade creditors	227,779	106,157
Taxes	4,250	-
Other liabilities	59,211	93,382
	<u>291,240</u>	<u>199,539</u>
	<u>15,055,097</u>	<u>15,231,642</u>

Statement of income and expenditure 2018

	Balance 2018	Balance 2017
INCOME		
Membership fees	81,618	91,604
Royalties	126,492	118,000
Interest and similar income	267,118	438,842
	<u>475,228</u>	<u>648,446</u>
Total income	475,228	648,446
EXPENSES		
Administration	243,941	195,004
Other expenses	162,397	180,221
European Neuropsychopharmacology	34,304	29,695
Other activities	271,393	33,837
Interest and similar charges	31,439	30,076
	<u>743,474</u>	<u>468,833</u>
Total expenses	743,474	468,833
Net result	-268,246	179,613
Appropriation of result		
Other reserves	-268,246	179,613

ECNP R&S

Balance sheet as at 31 December 2018 (in €)

(after appropriation of profit/losses)

	31-12-2018	31-12-2017
ASSETS		
CURRENT ASSETS		
Accounts receivable		
Debtors	12,487	7,375
Amounts owed by congress foundations	279,952	213,559
Amounts owed by other foundations	4,250	-
Taxes	6,099	4,854
Other accounts receivable	68,808	109,431
Prepayments and accrued income	39,466	45,564
	<hr/>	<hr/>
	411,062	380,783
Securities	8,870,862	8,357,789
Bank Deposits	4,108,011	4,873,073
	<hr/>	<hr/>
	13,389,935	13,611,645
RESERVES, FUNDS AND LIABILITIES		
RESERVES AND FUNDS		
Other reserves	13,065,315	13,351,045
Designated fund	-	55,506
	<hr/>	<hr/>
	13,065,315	13,406,551
CURRENT LIABILITIES		
Trade creditors	166,804	102,028
Amounts owed by congress foundations and college	12,884	53,384
Other liabilities	144,932	49,682
	<hr/>	<hr/>
	324,620	205,094
	<hr/>	<hr/>
	13,389,935	13,611,645

Statement of income and expenditure 2018

	Balance 2018	Balance 2017
INCOME		
Proceeds fundraising	384,311	444,374
NbN books	55,360	94,989
Interest and similar income	166,883	267,620
Grants	11,134	-
	<hr/>	<hr/>
Total income	617,688	806,983
EXPENSES		
Meetings and other activities	666,868	599,369
Other expenses	269,332	231,244
Interest and similar charges	22,724	-
	<hr/>	<hr/>
Total expenses	958,924	830,613
Net result	-341,236	-23,630
Appropriation of result		
Other reserves	-285,730	-23,630
Designated fund	-55,506	-
	<hr/>	<hr/>
	-341,236	-23,630



ECNP is the largest non-institutional supporter of education and research in applied neuroscience in Europe



Executive Director's report

The ECNP Office operates an agency model, providing services to the constituent ECNP foundations. Its time is apportioned according to the ratios: 20% to ECNP Association, 20% to ECNP R&S, 60% to the ECNP Congress.

The last couple of years have also seen the addition of a new category of 'clients' – European projects. As of 2018 the Office currently supports seven major Innovative Medicines Initiative (IMI) and Horizon 2020 projects with a variety of dissemination and organisational services. Configuring the Office to accommodate this additional activity, allowing in particular for the variances in its flow, remains an ongoing priority. A new member of staff, Maxime Besutti, has been recruited into our communications group to provide additional support in this area.

Meanwhile, the Office is also increasing its focus on the ECNP Congress. In 2008 management of the exhibition was brought inhouse, and the process begun of insourcing the entire congress registration apparatus, the last major piece of congress logistics currently contracted out. In doing so we believe we can not only achieve cost efficiencies, but – even more importantly – ensure a higher level of quality control and better service to our participants. The Office is also working on new initiatives to enhance the overall delegate experience, the results of which were seen at this year's Barcelona congress in, amongst others, the new 'Bubble' space, with its own mini-programme, and the highly successful 'Love Your Brain' campaign. These innovations are a tribute to the commitment and creativity of the ECNP Office staff, and I am extremely proud of their achievements.

Going forward, the focus of the Office will be on delivering the College's goals while necessarily working to contain costs.

Alexander Schubert
Executive Director



Report of the ECNP Review Board

The duty of the ECNP Review Board (ERB) is to assess continuously not only the quality of the scientific activities, but the whole governance of the ECNP.

The current composition of the ERB is:

- Chair: Hans-Jürgen Möller
- Members: Carlo Altamura, Naomi Fineberg, Kim Do

Kim Do followed Rafael Maldonado, who finished his term 2017. We thank him for his contributions!

The ERB usually has two meetings per year: we met at the occasion of the ECNP Workshop in Nice in March and at the beginning of the ECNP Congress.

Each of these meetings are associated with meetings between the ERB and the ECNP president and Executive Committee (EC) members.

The ERB meetings are full of intensive discussions and generate a lot of creative ideas and suggestions. The ECNP president and the EC-members were very open to listen to all the issues brought forward by the ERB.

It is outstanding what ECNP offers to its members and to the scientific community on different levels: annual congresses; smaller-sized and more targeted meetings, such as the Nice Workshop; educational meetings, among others on psychopharmacology (Oxford, Venice) or on methodology (Barcelona); research-oriented Networks to obtain (EU) funding; the ECNP journal (*European Neuropsychopharmacology*); the Neuroscience-based Nomenclature project, etc. All of these are on an excellent level and very well received.

The Neuroscience-based Nomenclature project, chaired by Joseph Zohar, was started by ECNP with further development including other relevant societies (CINP, ACNP, AsCNP). ECNP still has the lead.

The involvement of ECNP in the EU political scene is of the greatest importance for the development of our field, especially in terms of advocating for research funding.

The structure of ECNP and the related foundations is complex, but this reflects historical developments and tax-related necessities.

The whole governance of ECNP is in good order and very effective, among others due to the very competent and devoted administration in the Utrecht office.

ECNP together with the related foundations is in an outstanding financial situation. Its reserves provide a good buffer in the current difficult time of psychopharmacology.

ECNP has managed in the recent years to be more and more transparent for the members in terms of budgeting and its complex foundations structure.

The EC is fully aware of the current problems in psychopharmacology, especially those of the pharmaceutical industry, and how this will impact among others the support for congresses by the industry and finally the financial income of ECNP.

The EC has several ideas how to overcome these problems, among others by taking over more and more the congress organisation by the ECNP Office itself, by changing the focus more to neuroscience, and by trying to recruit other groups of participants, such as neurobiologically oriented psychologists.

The EC is open for other ideas, e.g. coming from the members, to prepare ECNP for the future and shape ECNP even more according to their needs.

The ERB brought forward the following suggestions, among others based on discussions with members, to the EC:

- ECNP should increase further the focus on gender-balance issues.
- ECNP should find ways to increase the active participation of scientists from middle and eastern Europe.
- ECNP should develop even more its role as scientific educator for clinicians, being the only society in Europe with this competency and mission.
- ECNP should consider the current misfit between the background of delegates (70% clinicians) and the objectives/activities of the organisation.
- It might be meaningful to give more people access to the Workshop on Clinical Research Methods and to implement new workshops, e.g. on preclinical research methodology.
- An increased involvement of neurologists and neuroscience-oriented psychologists seems advisable, not only for economic reasons, but also to enrich the scientific scope of ECNP.

Summary

- ECNP is in a very good shape under all aspects and very powerful.
- The whole governance is in optimal order and very effective.
- The planning for the future addresses well the upcoming challenges.


Hans-Jürgen Möller
Chair

Governance

ECNP operates as an amalgamation of different entities. These entities are legally autonomous and self-sustaining, but each represents the ECNP brand and serves co-ordinated goals.

These entities are:

- The European College of Neuropsychopharmacology (“ECNP Association”), a Swiss-constituted member society permanently based in the Netherlands
- The ECNP Research and Scholarship Foundation (“ECNP R&S”), a Dutch-constituted foundation legally domiciled in the Netherlands
- The ECNP Congress Foundations, one per congress; Dutch-constituted foundations legally domiciled in the Netherlands
- The Stichting Buro ECNP, a Dutch-constituted foundation legally domiciled in the Netherlands



ECNP Association, ECNP R&S and the ECNP Congress Foundations are all public-interest-serving entities (algemeen nut beogende instellingen – ‘ANBI’) under Dutch tax law.

The Stichting Buro ECNP is the legal umbrella housing the ECNP Office.

Membership

- 842 members
- 439 supporting members
- 1,281 total members

Top ten countries:

1. United Kingdom
2. Germany
3. The Netherlands
4. Spain
5. Italy
6. Sweden
7. United States
8. Russia
9. France
10. Switzerland

Re-imbusement

ECNP Association

The presidency comes with a grant of € 15,000 and each officer position (vice president, president-elect, past president, secretary, treasurer) € 4,000 to assist with secretarial expenses, payable to their institution of primary employment. Each member of the Executive Committee receives a lump sum of € 1,500 to cover incidental expenses related to their role.

ECNP R&S

Members of the board do not receive remuneration for their role.

ECNP Congress Foundations

The chair of the Scientific Programme Committee receives € 6,000 for secretarial assistance, payable to his/her institution of primary employment. Other members of the Scientific Programme Committee receive € 1,000 for the duration of their term to cover associated expenses.

Stichting Buro ECNP

Members of the board do not receive remuneration for their role.

ECNP Association

Executive Committee 2016-2019

Celso Arango, Spain, President
 Gitte Moos Knudsen, Denmark, President-elect
 Laurence Lanfumey, France, Vice-president
 Guy Goodwin, United Kingdom, Past-president
 Martien Kas, the Netherlands, Secretary
 Eduard Vieta, Spain, Treasurer

Councillors

Elisabeth Binder, Germany
 Damiaan Denys, the Netherlands
 Suzanne Dickson, Sweden
 Catherine Harmer, United Kingdom
 Stefano Pallanti, Italy
 Gil Zalsman, Israel

Non-voting Members

Gerry Dawson, United Kingdom, Co-opt Member
 Joop van Gerven, the Netherlands, Co-opt Member
 Astrid Linthorst, United Kingdom,
 Chair Scientific Programme Committee 29th, 30th,
 31st ECNP Congress
 Andreas Meyer-Lindenberg, Germany, Editor-in-Chief
European Neuropsychopharmacology
 Mark J. Millan, France, Co-opt Member
 Andreas Reif, Germany, Chair Scientific Programme
 Committee 32nd, 33rd, 34th ECNP Congress
 Alexander Schubert, the Netherlands,
 Executive Director

Award Committee

Andreas Meyer-Lindenberg, Germany, Chair
 Monica DiLuca, Italy
 Raquel Gur, United States
 Wim van den Brink, the Netherlands

Communication Committee

Damiaan Denys, the Netherlands, Chair
 Andreas Meyer-Lindenberg, Germany
 (Editor-in-Chief ENP)
 Jaanus Harro, Estonia
 Kamilla Miskowiak, Denmark
 Iria Grande, Spain

ECNP Review Board

Hans-Jürgen Möller, Germany, Chair
Carlo Altamura, Italy
Kim O. Do, Switzerland
Naomi Fineberg, United Kingdom

Nominating Committee (for the 2019-2021 Executive Committee)

Guy Goodwin, United Kingdom, past President, Chair
Celso Arango, Spain, President
Tomas Hökfelt, Sweden
Gitte Knudsen, Denmark, President-elect
Ruth McKernan, United Kingdom
Hans-Jürgen Möller, Germany
Wim van den Brink, the Netherlands

European Neuropsychopharmacology Editorial Board

Andreas Meyer-Lindenberg, Germany, Editor-in-Chief
Michael Davidson, Israel
Jaanus Harro, Estonia
Rafael Maldonado, Spain
Brian Morris, United Kingdom
Andreas Reif, Germany
Thomas. G. Schulze, Germany
Eduard Vieta, Spain

ECNP R&S

Board 2016-2019

Celso Arango, Spain, Chair
Gitte Moos Knudsen, Denmark, Secretary
Eduard Vieta, Spain, Treasurer

Early Career Advisory Panel (ECAP)

Marin Jukic, Sweden, Chair
Alla Chistol, Republic of Moldova
Judith Harrison, United Kingdom
Aiste Lengvenyte, Lithuania
Nils Opel, Germany
Guy Goodwin, United Kingdom, representative
Executive Committee

ECNP Networks Board

Gitte Moos Knudsen, Denmark, Chair
Nic van der Wee, the Netherlands,
Scientific Co-ordinator

ECNP Networks Taskforce

ADHD: Barbara Franke, the Netherlands;
Andreas Reif, Germany
Anxiety Disorders (ADRN): Borwin Bandelow, United
Kingdom; Katharina Domschke, Germany
Bipolar Disorders (ENBREC): Michael Bauer, Germany;
Lars Kessing, Germany; Ole Andreassen, Norway
Child and Adolescent Neuropsychopharmacology:
Alessandro Zuddas, Italy; Carmen Moreno, Spain
*Down Syndrome and Other Genetic Development
Disorders (DSG2D)*: Marie-Claude Potier, France;
Mara Dierssen, Spain
Experimental Medicines: Gerry Dawson, United Kingdom
Neuroimaging: Hilleke Hulshoff Pol, the Netherlands;
Nikolaos Koutsouleris, Germany
Nutrition: Suzanne Dickson, Sweden; Roger Adan,
the Netherlands
Obsessive Compulsive and Related Disorders (OCRN):
José Manuel Menchón, Spain
Preclinical Data Forum: Anton Bernalov, Germany;
Thomas Steckler, Belgium
Schizophrenia: Silvana Galderisi, Italy; István Bitter,
Hungary
Suicide: Danuta Wasserman, Sweden; Vladimir Carli,
Sweden
Traumatic Stress: Eric Vermetten, the Netherlands;
Joseph Zohar, Israel
*Prevention of mental disorders and mental health
promotion (TWG)*: Paolo Fusar-Poli, United Kingdom/
Italy

Educational Committee

Gil Zalsman, Israel, Chair
Avraham Avital, Israel
Katharina Domschke, Germany
Guy Goodwin, United Kingdom
Livia de Picker, Belgium
Ekin Sönmez, Turkey

Neuroscience-based Nomenclature Task Force

Joseph Zohar, Israel, Chair
Pierre Blier, Canada
Filippo Drago, Italy
Guy Goodwin, United Kingdom
David Kupfer, United States
Hans-Jürgen Möller, Germany
David Nutt, United States
Stephen Stahl, United States
Hiroyuki Uchida, Japan
Shigeto Yamawaki, Japan

New Frontiers Meeting Committee

Celso Arango, Spain, Chair
Gerry Dawson, United Kingdom
Hilkka Kärkkäinen, GAMIAN-Europe, Finland
Martien Kas, the Netherlands
Stephen R. Marder, United States
Hugh Marston, United Kingdom
Luca Pani, United States
Stephane Pollentier, Germany
Thomas Steckler, Belgium

Workshop Committee

Martien Kas, the Netherlands, Chair
Roger Adan, the Netherlands
Elisabeth Binder, Germany
Suzanne Dickson, Sweden
Katharina Domschke, Germany
Catherine Harmer, United Kingdom
Jaanus Harro, Estonia
Marin Jukic, Sweden
Gitte Knudsen, Denmark
Oscar Marin, Spain
Mark Millan, France
Andreas Reif, Germany

31st ECNP Congress Foundation

Board

Celso Arango, Spain, Chair and Treasurer
Alexander Schubert, the Netherlands, Secretary
Astrid Linthorst, United Kingdom

Scientific Programme Committee

Astrid Linthorst, United Kingdom, Chair
Josefina Castro-Fornieles, Spain
Kim Do, Switzerland
Joop van Gerven, the Netherlands
Jeremy Hall, United Kingdom
Marion Leboyer, France
Paul Lucassen, the Netherlands
Andreas Meyer-Lindenberg, Germany, Editor-in-Chief
European Neuropsychopharmacology
Kamilla Miskowiak, Denmark
Agneta Nordberg, Sweden
Stefano Pallanti, Italy
Andreas Reif, Germany
Marco Riva, Italy
Rainer Spanagel, Germany

Mark Weiser, Israel
Aysegul Yildiz, Turkey
Gil Zalsman, Israel, Chair ECNP Educational
Committee

Scientific Advisory Panel for 2017-2020

Roger Adan, the Netherlands
Laura Airas, Finland
Pino Alonso, Spain
Frank Bellivier, France
Anton Y. Bernalov, Germany
István Bitter, Hungary
Michael Bloomfield, United Kingdom
Jan Booij, the Netherlands
Jan K. Buitelaar, the Netherlands
Jocelyne Caboche, France
Josefina Castro-Fornieles, Spain
Annamaria Cattaneo, United Kingdom
Ginetta Collo, Italy
Andrea Danese, United Kingdom
Andrea de Bartolomeis, Italy
Suzanne L. Dickson, Sweden
Katharina Domschke, Germany
Filippo Drago, Italy
Anne Eckert, Switzerland
Angelika Erhardt, Germany
Mia Ericson, Sweden
Karen Ersche, United Kingdom
David P. Finn, Ireland
Gabriele Fischer, Austria
Kevin C.F. Fone, United Kingdom
Barbara Franke, the Netherlands
Christine Freitag, Germany
Vibe G. Frokjaer, Denmark
Silvana Galderisi, Italy
Alexander Gerhard, United Kingdom
Mark A. Geyer, United States
Philip Gorwood, France
Iria Grande, Spain
Edna Grünblatt, Switzerland
Antoni Gual, Spain
Gregor Hasler, Switzerland
Martin Hatzinger, Switzerland
Judith Homberg, the Netherlands
Iiris Hovatta, Finland
Michal Hrdlicka, Czech Republic
Evgeny Krupitsky, Russia
Marion Leboyer, France
Klaus-Peter Lesch, Germany
Stefan Leucht, Germany
Paul John Lucassen, the Netherlands
Anabel Martinez-Aran, Spain

David Mataix-Cols, Sweden
Raymond Mongeau, France
Carmen Moreno, Spain
Arne Mørk, Denmark
Rainald Mössner, Germany
Dieter Naber, Germany
Inga Neumann, Germany
Florence Noble, France
Mariusz Papp, Poland
Mara Parellada, Spain
Walter Pirker, Austria
Edith Pomarol-Clotet, Spain
Marie-Claude Potier, France
Christopher Pryce, Switzerland
Andreas Reif, Germany
Emma Robinson, United Kingdom
Michelle Roche, Ireland
Henricus G. Ruhe, the Netherlands
Rainer Rupperecht, Germany
Janusz K. Rybakowski, Poland
David A. Slattery, Germany
Iris E.C. Sommer, the Netherlands
Daniel Souery, Belgium
Florence Thibaut, France
Marta Torrens, Spain
Elizabeth Tunbridge, United Kingdom
Wim van den Brink, the Netherlands
Guido van Wingen, the Netherlands
Louk J. Vanderschuren, the Netherlands
Elisabet Vilella, Spain
Odile Viltart, France
Ina Weiner, Israel
Abraham Weizman, Israel
Sue Wilson, United Kingdom
Aysegül Yildiz, Turkey
Alessandro Zuddas, Italy
Koen Schruers, the Netherlands

Stichting Buro ECNP

Board

Celso Arango, Chair
Martien Kas, Secretary/Treasurer

ECNP Office

Alexander Schubert, Executive Director
Iris Allebrandi, Director Congresses & Meetings
Ellen van den Berg, Director Operations
Ligia Bohn, Senior Project Manager Communication
Godelieve Escartín, Senior Project Manager
Congresses & Meetings
Eline Dimmendaal, Project Manager Congresses &
Meetings
Annemieke Heuvink, Project Manager Congresses &
Meetings
Melinda Spitzer, Project Manager Congresses &
Meetings
Corine ten Brink, Project Manager Science & Education
Wendy Schouten, Project Manager Science &
Education
Petra Hoogendoorn, Project Manager Science,
Education & Communication
Matteo Bason, Scientific Co-ordinator
Vandana Kamath, Assistant Project Manager
Communication
Maxime Besutti, Assistant Project Manager
Communication
Rilana Rahaël, Financial Administrative Assistant

Key Identification Numbers

ECNP Association

VAT number: NL823523974B01
RSIN: 823523974 R&S

ECNP R&S

VAT number: NL807967087B01
RSIN: 807967087
Chamber of commerce number: 41215196



ECNP *neuroscience
applied*

ECNP Office

T: +31 88 75 69 555

E: secretariat@ecnp.eu

www.ecnp.eu

Postal Address

PO Box 85410

3508 AK Utrecht

The Netherlands

Visiting Address

Bolognalaan 28

3584 CJ Utrecht

The Netherland

